MiR-650 inhibits proliferation, migration and invasion of rheumatoid arthritis synovial fibroblasts by targeting AKT2 - 13/03/17
, Haiyan Chen, Qin Zhang, Jin Xu, Qing Shi, Meimei Wang| pages | 7 |
| Iconographies | 6 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Background and objectives |
This study was aimed to investigate the effects of miR-650 on the proliferation, migration, invasion and apoptosis of rheumatoid arthritis synovial fibroblasts (RASFs).
Methods |
Synovial tissue samples were collected from 16 rheumatoid arthritis (RA) patients and 13 patients with joint trauma undergoing joint replacement surgery. The RASFs were isolated and cultured. MiR-650 and AKT2 expressions in both synovial tissues and cells were detected using the quantitative real-time PCR (qRT-PCR), western blot and immunohistochemistry (IHC). Dual luciferase reporter gene assay was employed to evaluate the effect of miR-650 on the luciferase activity of AKT2. Then RASFs were transfected with miR-650 mimics, miR-650 inhibitors and pLenti6/V5-AKT2 respectively. And changes in cellular proliferation, migration, invasion and apoptosis were detected through MTT assay, wound healing assay, Transwell invasion assay and flow cytometry analysis, respectively.
Results |
MiR-650 was significantly down-regulated in RASFs than normal cells, whereas AKT2 was up-regulated in RASFs. Dual luciferase reporter gene assay showed that miR-650 could specifically bind to the 3′UTR of AKT2 and significantly repress the luciferase activity. MiR-650 significantly decreased the expression of AKT2. Down-regulation of miR-650 or up-regulation of AKT2 could increase proliferation, migration, invasion of RASFs, and decrease RASFs apoptosis. The conversed results were observed, when miR-650 was up-regulated in RASFs.
Conclusions |
MiR-650 could inhibit the proliferation, migration and invasion of RASFs through targeted regulation of AKT2 expression.
Le texte complet de cet article est disponible en PDF.Keywords : miR-650, AKT2, Rheumatoid arthritis, Synovial fibroblasts
Plan
Vol 88
P. 535-541 - avril 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?
